How have TBIO shares performed in 2024?

Telesis Bio's stock was trading at $0.3990 at the start of the year. Since then, TBIO shares have decreased by 24.3% and is now trading at $0.3020. View the best growth stocks for 2024 here .

Are investors shorting Telesis Bio?

Telesis Bio saw a decline in short interest during the month of March. As of March 31st, there was short interest totaling 100,400 shares, a decline of 55.6% from the March 15th total of 226,300 shares. Based on an average trading volume of 742,000 shares, the days-to-cover ratio is presently 0.1 days. Approximately 1.1% of the company's shares are sold short. View Telesis Bio's Short Interest .

When is Telesis Bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our TBIO earnings forecast .

How were Telesis Bio's earnings last quarter?

Telesis Bio, Inc. (NASDAQ:TBIO) released its quarterly earnings data on Thursday, March, 28th. The company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.02. The firm had revenue of $6.98 million for the quarter. Telesis Bio had a negative net margin of 173.78% and a negative trailing twelve-month return on equity of 176.47%.

What guidance has Telesis Bio issued on next quarter's earnings?

Telesis Bio updated its fourth quarter 2023 earnings guidance on Tuesday, February, 27th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $7.0 million-$7.0 million, compared to the consensus revenue estimate of $9.5 million.

What is Craig J. Tuttle's approval rating as Telesis Bio's CEO?

13 employees have rated Telesis Bio Chief Executive Officer Craig J. Tuttle on Glassdoor.com . Craig J. Tuttle has an approval rating of 5% among the company's employees. This puts Craig J. Tuttle in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Telesis Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Telesis Bio investors own include Inovio Pharmaceuticals (INO) , Dynavax Technologies (DVAX) , Gilead Sciences (GILD) , Novavax (NVAX) , Pfizer (PFE) , Moderna (MRNA) , Johnson & Johnson (JNJ) , Sorrento Therapeutics (SRNE) , Vaxart (VXRT) and VBI Vaccines (vbiv) .

When did Telesis Bio IPO?

Telesis Bio (TBIO) raised $100 million in an initial public offering (IPO) on Thursday, June 28th 2018. The company issued 7,700,000 shares at $12.00-$14.00 per share. Citigroup, Leerink Partners and Evercore ISI served as the underwriters for the IPO.

How do I buy shares of Telesis Bio?

Shares of TBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:TBIO

Telesis Bio (TBIO) Stock Price, News & Analysis

→ Tiny Biotech Stock Wins $75 Billion Patent (From Behind the Markets) (Ad)

Free TBIO Stock Alerts

$0.31

-0.02 (-6.65%)

(As of 05:21 PM ET)

Compare

Today's Range: $0.30
▼
$0.35
50-Day Range: $0.31
▼
$0.78
52-Week Range: $0.30
▼
$3.01

Volume: 161,686 shs
Average Volume: 643,841 shs
Market Capitalization: $9.30 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Get Telesis Bio alerts:

Ad Crypto 101 Media

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

About Telesis Bio Stock (NASDAQ:TBIO)

Telesis Bio, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. Its solutions include BioXp system, including BioXp 3250 system, BioXp 9600 system, and BioXp DBC, which are empowers researchers to go from a digital DNA sequence to endpoint-ready synthetic DNA; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice; BioXp kits, such as BioXp De Novo kits, BioXp select kits, BioXp next generation sequencing kits, and BioXp DBC kits, which contains building blocks and reagents, including its Gibson Assembly branded reagents, for specific synthetic biology workflow applications; Benchtop reagents that contain all the reagents necessary to proceed with a specific synthetic biology workflow on the benchtop using products generated on the BioXp system; and short oligo ligation assembly enzymatic DNA synthesis designs to significantly reduce timelines for constructing synthetic DNA, RNA, and proteins compared to traditional chemical synthesis, paving the way for more efficient and effective development of mRNA-based vaccines, diagnostics, therapeutics, and personalized medicines. It also serves government institutions, contract research organizations, and synthetic biology companies. The company was formerly known as Codex DNA, Inc. and changed its name to Telesis Bio Inc. in November 2022. Telesis Bio, Inc. was incorporated in 2011 and is headquartered in San Diego, California.

TBIO Stock Price History

30 days | 90 days | 365 days | Advanced Chart

TBIO Stock News Headlines

April 18, 2024 | msn.com

Telesis Bio announces leadership transition amid new commercial focus

April 18, 2024 | globenewswire.com

Telesis Bio Inc. announces strategic focus on game-changing Gibson SOLA enzymatic DNA synthesis (EDS) platform and BioXp mRNA solutions and announces new leadership

April 19, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

March 29, 2024 | msn.com

TBIO Stock Earnings: Telesis Bio Misses EPS, Misses Revenue for Q4 2023

March 28, 2024 | globenewswire.com

Telesis Bio Reports Fourth Quarter and Full Year 2023 Financial Results

March 3, 2024 | morningstar.com

Telesis Bio Inc TBIO

February 26, 2024 | finance.yahoo.com

Telesis Bio Announces Select Preliminary Fourth Quarter 2023 Financial Results

February 26, 2024 | globenewswire.com

Telesis Bio Announces Select Preliminary Fourth Quarter 2023 Financial Results

April 19, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

February 24, 2024 | benzinga.com

Telesis Bio Stock (NASDAQ:TBIO), Insider Trading Activity

February 23, 2024 | investorplace.com

Why Is Telesis Bio (TBIO) Stock Up 29% Today?

February 23, 2024 | msn.com

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

February 18, 2024 | finance.yahoo.com

Telesis Bio, Inc. (TBIO)